Conclusion
Our study demonstrated that Veregen® is not only safe but results in at
least a partial clinical resolution of uVIN lesions in all patients.
Furthermore, we show that Veregen® treatment also offers symptoms
improvement and a potentially better quality of life. Together, our
result suggests that further phase 3 randomised controlled study is
warranted to evaluate the efficacy of Veregen® in a sizeable multicentre
setting to include patients with primary and recurrence disease. Lastly,
as Veregen® ointment is relatively well tolerated with minimal side
effects, there is a possibility for increasing treatment duration beyond
currently recommended 16 weeks, as prolonged treatment may lead to a
histological resolution of uVIN.